• Navignostics

  Led · Convertible Note · Sep 2022

  Navignostics combines AI-driven software with single-cell resolved spatial proteomic tumor data to guide targeted and immuno-oncology therapy selection tailored to each patient’s tumor phenotype. The company also offers advanced services to pharmaceutical companies to accelerate oncology drug development and enable discovery of companion diagnostic biomarkers. Navignostics is a spin-off from the University of Zurich and was founded in April 2022 by Jana Fischer, Stephane Chevrier, Andrea Jacobs and Bernd Bodenmiller. The team plans to use its recent financing to develop its first diagnostic product, establish certified processes, and move into dedicated laboratory and office premises. Management intends to expand engagement with clinical, biotech and pharma partners and grow its scientific and commercial team. No operating metrics (revenue/users) were disclosed in the article. Navignostics leverages spatial single-cell proteomics to perform advanced analyses of tumor samples aimed at identifying optimal treatments for individual cancer patients and accelerating cancer drug development. The company is developing the NX product to provide insights into drug mechanisms and tumor features for companion diagnostic development. Navignostics plans to use new funding to expand a world-leading team of scientists and business professionals and to boost NX product development. The company received an initial CHF1 million convertible loan from the UZH Life Sciences Fund to drive company and product development. Navignostics is a spin-off from Bernd Bodenmiller’s lab at the University of Zurich and was founded in April 2022 by Stephane Chevrier, Andrea Jacobs, Jana Fischer and Bernd Bodenmiller. The funding is described as an initial boost while the company is in the process of putting together a seed financing round.

No current team members are available.